Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer
Status: COMPLETED
Study type: INTERVENTIONAL
Conditions: Advanced, Androgen Receptor Positive Triple Negative Breast Cancer
Interventions: DRUG: Enzalutamide
Sponsor: Pfizer
Collaborators: Astellas Pharma Inc|Medivation LLC, a wholly owned subsidiary of Pfizer Inc.